Valuation: Lexaria Corp

Market Cap 15.77M 13.82M 12.77M 11.75M 22.17M 1.52B 22.52M 153M 59.88M 744M 59.21M 57.91M 2.56B P/E 2026 *
-2.36x
P/E 2027 * -2.05x
Enterprise Value 15.77M 13.82M 12.77M 11.75M 22.17M 1.52B 22.52M 153M 59.88M 744M 59.21M 57.91M 2.56B EV / Sales 2026 *
788x
EV / Sales 2027 * 11.2x
Free-Float
96.68%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 31/08/2024
Director of Finance/CFO 66 01/10/2024
President 55 15/04/2015
Director TitleAgeSince
Chairman 65 26/10/2006
Director/Board Member 57 14/01/2025
Director/Board Member 72 08/07/2011
Change 5-day change 1-year change 3-year change Capi.($)
-1.74%-1.59%+52.60%+150.76% 1,051B
-1.44%-3.05%+52.04%+48.41% 609B
-8.31%+2.11%+36.99%+78.09% 450B
-0.75%+0.30%+29.77%+21.15% 330B
-1.52%-1.19%+34.46%+35.35% 284B
-1.70%-1.82%+20.99%+15.74% 263B
-0.58%+1.11%-20.18%-40.59% 223B
+0.15%+1.34%+23.46%+56.62% 198B
-0.36%+1.69%+23.40%+67.14% 167B
Average -0.98%+0.10%+28.17%+48.08% 397.23B
Weighted average by Cap. -1.15%-0.58%+37.15%+72.05%

Financials

2026 *2027 *
Net sales 20K 17.53K 16.2K 14.9K 28.12K 1.93M 28.57K 194K 75.95K 944K 75.1K 73.46K 3.25M 1.4M 1.23M 1.14M 1.05M 1.97M 135M 2M 13.59M 5.33M 66.2M 5.27M 5.15M 228M
Net income -6.64M -5.82M -5.38M -4.95M -9.33M -640M -9.48M -64.32M -25.21M -313M -24.93M -24.39M -1.08B -8.95M -7.84M -7.25M -6.67M -12.58M -863M -12.78M -86.68M -33.98M -422M -33.6M -32.86M -1.45B
Net Debt - -
Logo Lexaria Corp
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-